Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½É¹Ú¼¼µ¿ ȯÀÚ¿¡¼­ ¾Æ½ºÇǸ° Åõ¿©±â°£°ú °á¸·ÇÏÃâÇ÷ ¹ß»ý·üÀÇ ºÐ¼® Analysis of Duration of Aspirin Administration and Incidence of Subconjunctival Hemorrhage in Patients with Atrial Fibrillation

´ëÇѽðúÇÐȸÁö 2019³â 21±Ç 4È£ p.489 ~ 496
ÃÖÀ±Á¤, ÃÖÀ±¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖÀ±Á¤ ( Choy Yoon-Jung ) 
Eulji University College of Health Sciences Department of Optometry

ÃÖÀ±¼ö ( Choy Yoon-Soo ) 
Eulji University Eulji Foundation External Cooperation Task Force Team

Abstract

¸ñÀû : º» ¿¬±¸ÀÇ ¸ñÀûÀº Ç÷Àü ¿ëÇØÁ¦¸¦ »ç¿ëÇÑ ½É¹æ¼¼µ¿ ȯÀÚµéÀ» Àå±â°£ ÃßÀû °üÂûÇÏ¿© °á¸·ÇÏ ÃâÇ÷ÀÇ ¹ß»ý·ü°ú À§Çè ÀÎÀÚ¸¦ Á¶
»çÇϱâ À§ÇÔÀÌ´Ù.
¹æ¹ý : 2002³âºÎÅÍ 2006³â±îÁö °Ç°­º¸Çè°ø´Ü ÀÚ·á¿¡¼­ ½É¹æ¼¼µ¿À¸·Î Áø´Ü¹ÞÀº ȯÀÚµéÀ» 2007³âºÎÅÍ 2013³â±îÁö °æ°ú °üÂû ÇÏ¿´´Ù. ¾Æ½ºÇǸ° »ç¿ë°ú °á¸·ÇÏ ÃâÇ÷°úÀÇ °ü°è¸¦ ¾Ë¾Æº¸±â À§ÇØ ½É¹æ¼¼µ¿ ȯÀÚµéÀÇ ¾Æ½ºÇǸ° º¹¿ë ±â°£°ú °á¸·ÇÏ ÃâÇ÷ ¹ß»ý·üÀ» ºÐ¼®ÇÏ¿´´Ù.

°á°ú : ÃÑ 7,471¸íÀÇ ½É¹æ¼¼µ¿ ȯÀÚ°¡ ¼±ÅõǾú°í, À̵é Áß °á¸·ÇÏ ÃâÇ÷Àº 893¸íÀÌ ¹ß»ýÇÏ¿´´Ù. °á¸·ÇÏ ÃâÇ÷ÀÌ ¹ß»ýÇÑ 289¸íÀÇ È¯ÀÚµéÀº 90¸í(31.1%)ÀÌ 1³âÀÌÇÏ, 1~4³â 97¸í(33.6%), 4³âÀÌ»ó 102¸í(35.3%)·Î ¾Æ½ºÇǸ°À» º¹¿ëÇÏ¿´´Ù. ¾Æ½ºÇǸ°À» 1~4³â, >4³âµ¿¾È º¹¿ëÇßÀ» ¶§ °á¸·ÇÏ ÃâÇ÷ ¹ß»ý À§Çè ºñÀ²Àº °¢°¢ 0.856(95% CI, .642-1.14, p=.287), 0.699(95% CI, .526-.929, p=.014)¿´´Ù. ¾Æ½ºÇǸ°À» 4³âÀÌ»ó º¹¿ëÇßÀ» ¶§´Â 1³âÀÌÇϺ¸´Ù À§Çèµµ°¡ À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´´Ù(p=.014). ¾Æ½ºÇǸ°À» º¹¿ëÇÑÁö 11³â°ÀÇ °á¸·ÇÏ ÃâÇ÷ÀÇ ´©Àû ¹ß»ý·üÀº ¾Æ½ºÇǸ°À» <1³â,1~4³â, >4³â º¹¿ëÇßÀ» ¶§ °¢°¢ 45%, 37%, 35%¿´´Ù.

°á·Ð : °á¸·ÇÏ ÃâÇ÷ÀÇ ¹ß»ýÀº ³ªÀÌ µç ½É¹æ¼¼µ¿ ȯÀÚ¿¡¼­ ´õ ³ô¾ÒÀ¸³ª, Àå±â°£ÀÇ ¾Æ½ºÇǸ° »ç¿ëÀ¸·Î ÀÎÇÑ °á¸·ÃâÇ÷ÀÇ ¹ß»ý À§Çè°ú ´©Àû ¹ß»ý·üÀº ³ôÁö ¾Ê¾Ò´Ù. ÇÏÁö¸¸, ¹Ýº¹ÀûÀÌ°í Áö¼ÓÀûÀÎ °á¸·ÇÏ ÃâÇ÷ÀÌ ÀÖÀ» ¶§, ȯÀÚÀÇ Àü½Å »óÅÂ¿Í Ã³¹æ¾àÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ Ãß°¡ Æò°¡°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù.

Purpose : The purpose of this study was to investigate the incidence and risk factors of subconjunctival hemorrhage (SCH) in long-term follow-up of patients with atrial fibrillation(AF) using thrombolytic agents.

Methods : Patients with AF in the National Health Insurance Corporation database from 2002to 2006 were followed up from 2007 to 2013. To evaluate the relationship between aspirin use and SCH, we analyzed the duration of aspirin and the incidence of SCH in patients with AF.

Results : A total of 7,471 AF patients were selected, 893 of whom were SCH. In 289 patients with SCH, 90(31.1%) patients had taken aspirin for <1 year: 97(33.6%) for 1~4 years: 102(35.3%) for >4 years. Hazards ratio of developing SCH after taking aspirin for 1~4 and >4 years was 0.856(95% confidence interval (CI), .642-1.14, p=.287), and 0.699(95% CI, .526-.929, p=.014), respectively. When taking aspirin for more than 4 years, the risk was significantly lower than when taking less than 1 year(p =.014). The cumulative incidence rate of SCH was 45%, 37% and 35% for aspirin users of <1 year, 1~4 years, and >4 years, respectively, in the 11th year of taking aspirin.

Conclusion : The incidence of SCH was higher in older AF patients, but the occurrence risk of SCH and cumulative incidence rate due to prolonged usage of aspirin were not high. However, when there is recurrent and persistent SCH, further evaluation of the patient¡¯s systemic disorder and side effects of prescription drugs is needed.

Å°¿öµå

¾Æ½ºÇǸ°; ½É¹æ ¼¼µ¿; °á¸·ÇÏ ÃâÇ÷
Aspirin; Atrial fibrillation; Subconjunctival hemorrhage

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI